Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd
This study has two parts. In the Dose Escalation parts, D3S-001 will be given to all eligible participants, and will be administered orally. In the Dose Expansion part, D3S-001 will be administered orally in people with selected cancer types.